Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
The Journal of Toxicological Sciences
|
February 4, 2021
Development challenges associated with rAAV-based gene therapies
Michael W Bolt, Joseph T Brady, Lawrence O Whiteley, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
November 6, 2019
Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L
Michael W Bolt, Fei Hua, Karrie A Brenneman, et al.
Therapeutic Advances in Gastroenterology
|
June 22, 2019
The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product
Joseph E McClellan, Hugh D Conlon, Michael W Bolt, et al.
Frontiers in Toxicology
|
June 14, 2023
Sex-related differences in retinal function in Wistar rats: implications for toxicity and safety studies
Cheryl Tyszkiewicz, Seo-Kyoung Hwang, Balasubramanian Manickam, et al.
Toxicology and Applied Pharmacology
|
September 13, 2017
Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database
Thomas M Monticello, Thomas W Jones, Donna M Dambach, et al.
Science Translational Medicine
|
August 26, 2016
Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis
Tovo David, Yun Cheol Kim, Lauren K Ely, et al.
Molecular Therapy. Methods & Clinical Development
|
October 7, 2020
Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective
Michael W Bolt, Laurence O Whiteley, Jessica L Lynch, et al.
Advances in Therapy
|
September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)
Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
Journal of Medicinal Chemistry
|
June 8, 2018
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
Allyn T Londregan, Liuqing Wei, Jun Xiao, et al.
Angewandte Chemie (International Ed. in English)
|
October 27, 2017
Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis
Kim F McClure, David W Piotrowski, Donna Petersen, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
The Journal of Toxicological Sciences
|
February 4, 2021
Development challenges associated with rAAV-based gene therapies
Michael W Bolt, Joseph T Brady, Lawrence O Whiteley, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis
|
November 6, 2019
Evaluation of biomarkers for monitoring thrombogenic potential of FXaI16L
Michael W Bolt, Fei Hua, Karrie A Brenneman, et al.
Therapeutic Advances in Gastroenterology
|
June 22, 2019
The 'totality-of-the-evidence' approach in the development of PF-06438179/GP1111, an infliximab biosimilar, and in support of its use in all indications of the reference product
Joseph E McClellan, Hugh D Conlon, Michael W Bolt, et al.
Frontiers in Toxicology
|
June 14, 2023
Sex-related differences in retinal function in Wistar rats: implications for toxicity and safety studies
Cheryl Tyszkiewicz, Seo-Kyoung Hwang, Balasubramanian Manickam, et al.
Toxicology and Applied Pharmacology
|
September 13, 2017
Current nonclinical testing paradigm enables safe entry to First-In-Human clinical trials: The IQ consortium nonclinical to clinical translational database
Thomas M Monticello, Thomas W Jones, Donna M Dambach, et al.
Science Translational Medicine
|
August 26, 2016
Factor XIa-specific IgG and a reversal agent to probe factor XI function in thrombosis and hemostasis
Tovo David, Yun Cheol Kim, Lauren K Ely, et al.
Molecular Therapy. Methods & Clinical Development
|
October 7, 2020
Nonclinical Studies that Support Viral Vector-Delivered Gene Therapies: An EFPIA Gene Therapy Working Group Perspective
Michael W Bolt, Laurence O Whiteley, Jessica L Lynch, et al.
Advances in Therapy
|
September 3, 2016
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade<sup>®</sup> (Infliximab)
Mazin Derzi, Theodore R Johnson, Ahmed M Shoieb, et al.
Journal of Medicinal Chemistry
|
June 8, 2018
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents
Allyn T Londregan, Liuqing Wei, Jun Xiao, et al.
Angewandte Chemie (International Ed. in English)
|
October 27, 2017
Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis
Kim F McClure, David W Piotrowski, Donna Petersen, et al.
Page
of 1